title: Effect of bradykinin on cultured bovine corneal endothelial cells.
abstract: OBJECTIVE
  To clarify the effect of bradykinin on cytosolic free calcium mobilization and cell proliferation in cultured bovine corneal endothelial cells (BCEC).
  
  
  METHODS
  The cytosolic free calcium concentration (Ca2+]i) was measured with the InCa(TM) Imaging System after the treatment of bradykinin (10(-11) to 10(-7) M) alone or with the pretreatments of EGTA, bradykinin receptor (Bk1 and Bk2) antagonists and an inhibition of phospholipase C (U-73122). Also, the effect of bradykinin on cell proliferation in BCEC was evaluated using cell counts.
  
  
  RESULTS
  In BCEC, [Ca2+]i in the resting state was 87 +/- 9 nM. Bradykinin induced an increment of [Ca2+]i in a concentration-dependent manner and its 50% effective concentration was approximately 5 x 10(-11) M. A [Ca2+]i increment at 10(-8) M bradykinin was inhibited with the pretreatment of EGTA, an extracellular calcium chelator. U-73122 (5 x 10(-6) M) attenuated the bradykinin-induced [Ca2+]i increment. The pretreatment of HOE-140 (Bk2 antagonist) almost attenuated the bradykinin (10(-8) M)-induced [Ca2+]i increase, but des-Arg9-[Leu(8)]-bradykinin (Bk1 antagonist) did not suppress it. To investigate the physiological effect of bradykinin, the effect of bradykinin on cell proliferation was studied. 10(-8) M of bradykinin produced a significant increase in cell numbers. This mitogenic effect of bradykinin was inhibited by the Bk2 antagonist.
  
  
  CONCLUSIONS
  Bradykinin-induced stimulation of the signal transduction pathway in BCEC is coupled with the Bk2 type receptor. Furthermore, bradykinin produces the mitogenic effect in BCEC.
authors.affiliation: Department of Ophthalmology, College of Medicine, Catholic University of Korea, Seoul, Korea.
authors.forename: S W
authors.initials: SW
authors.lastname: Yang
authors.forename: W K
authors.initials: WK
authors.lastname: Lee
authors.forename: E J
authors.initials: EJ
authors.lastname: Lee
authors.forename: K Y
authors.initials: KY
authors.lastname: Kim
authors.forename: Y
authors.initials: Y
authors.lastname: Lim
authors.forename: K H
authors.initials: KH
authors.lastname: Lee
authors.forename: H K
authors.initials: HK
authors.lastname: Rha
authors.forename: T W
authors.initials: TW
authors.lastname: Hahn
mesh_terms: D000818:Animals; D001920:Bradykinin / Q000031:analogs & derivatives / Q000494:pharmacology*; D065168:Bradykinin Receptor Antagonists; D002118:Calcium / Q000378:metabolism; D002417:Cattle; D002452:Cell Count; D002455:Cell Division / Q000187:drug effects; D002478:Cells, Cultured; D004305:Dose-Response Relationship, Drug; D004533:Egtazic Acid / Q000494:pharmacology; D004728:Endothelium, Corneal / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism; D004963:Estrenes / Q000494:pharmacology; D015544:Inositol 1,4,5-Trisphosphate / Q000378:metabolism; D011760:Pyrrolidinones / Q000494:pharmacology; D043782:Receptor, Bradykinin B2; D018002:Receptors, Bradykinin / Q000378:metabolism; D015398:Signal Transduction / Q000187:drug effects; D010738:Type C Phospholipases / Q000037:antagonists & inhibitors / Q000378:metabolism
chemical_list: D065168:Bradykinin Receptor Antagonists; D004963:Estrenes; D011760:Pyrrolidinones; D043782:Receptor, Bradykinin B2; D018002:Receptors, Bradykinin; C060229:1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione; D004533:Egtazic Acid; C065679:icatibant; D015544:Inositol 1,4,5-Trisphosphate; D010738:Type C Phospholipases; D001920:Bradykinin; D002118:Calcium